Home - GHR-15 Home - hGH - GHR15 Info - Order GHR-15
Somatotropin & Adult hGH Deficiency
Somatotropin or human growth hormone is secreted by the pituitary gland under the influence of growth hormone releasing hormone. In December 1996, at the 4th Annual meeting of the American Academy of anti-aging Medicine, it was reported by Dr. Thierry Hertoghe, MD that this secretion falls with age from 500mg at 20 years to 200mg at 40 years, and 25mg at 80 years with a concomitant fall of IGF-1(Insulin Like Growth Factor I or Somatomedin C), levels from 240ng/ml at 30years, 200ng/ml at 40years, and 40ng/ml at 80 years1,2..
|
It has been known as early as 1979 that IGF-I is the main effector of growth hormone activity.3 IGF-I or Somatomedin C is the major member of a family of proteins synthesized by the liver in response to growth hormone stimulus. Further studies have revealed that it circulates in the peripheral blood bound on a tertiary complex with IGFBP-3 and acid labile subunit (ALS)4. In this form Somatomedin C(IGF-I) can not leave circulation. An increase in the ratio of Somatomedin C (IGF1) to either IGFBP-3 or ALS has been reported to increase the bioavailability of the IGFs. However, this would only be true if the total Somatomedin C(IGF-I) and IGF-II exceeded the binding capacity of IGFBP-3. This has yet to be demonstrated. The measurement of IGFB-3 clinically has yet to be proved of value in either diagnosing or monitoring therapy of growth hormone deficiency. The increasing incidence of Somatomedin C (IGF-I) reduction with age, results in a clinical hyposomatotropin deficiency syndrome. See IGF Testing below The following are lists of symptoms and clinical observations that have been noticed:
These changes are often accompanied by an increase in atherosclerosis and an increase in cardiovascular mortality.7 |
HGH Therapy with Amino Acid Releasers
Oral amino acids is an exciting approach to stimulate the production and release of hGH from the pituitary, a fact used in the investigation of pituitary function in the young child and adult. A mixture of arginine, (2g) lysine(1g), ornithine(2g), and glutamine(1g), has been recommended as a supplement to induce hGH release and consequently increase the IGF-1 levels8. This blend of amino acids can be found in the product GHR15.
There are many studies in young people showing that these amino acids will produce an increase in the plasma levels of IGF-1, and also reports of success using this regime in the elderly, there has been, to date, no published scientific study showing that indeed these four amino acids will cause an appropriate increase in the levels of hGH and consequently IGF-1 following long term therapy.
This combination of amino acids has been put together as supplement mixtures such as GHR-15 which often include other supplements as well as the four amino acids. Studies have been conducted by laboratories on the efficacy of oral amino acids, either as amino acids, or as a prepared nutritional supplement.
IGF-I Testing
The measurement of random human growth hormone in serum is of very little diagnostic value because levels change dramatically in response to various stimuli. Dynamic tests of pituitary function such as the arginine infusion test and insulin hypoglycemia with measurements of growth hormone levels are valuable but not practical in an outpatient environment. Therefore the measurement of Somatomedin C (IGF-1) is the best indicator of adult growth hormone deficiency in the outpatient setting, and the test of choice to monitor growth hormone therapy.
The diagnosis of adult human growth hormone deficiency should be considered in every adult patient who presents with suggestive symptoms. The diagnosis should be confirmed by measurement of Somatomedin C(IGF1).
References for Somatomedin C (IGF-1)
1. Hertoghe T. Growth hormone therapy in aging adults 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
2. Bouillanne O, Rainfray M, Tissandier O et al. Growth hormone in elderly people:an age-delaying drug? Fundan Clin Pharmacol 1996 10 (5) 416-30.
3. Merimee TJ. Growth hormone secretion and action. Endocrinology DeGroot et al (eds) New York, NY 1979.
4. Thoren M, Hilding M, Baxter RR et al. Serum insulin like growth factor 1(IGF1), IGF binding protein -1 and -3 and the acid labile subunit as serum markers of body composition during growth hormone therapy in adults with GH deficiency. J Clin Endorinol Metabol 1997; 82 (1): 223-8.
5. Johansson JO , Landin K, Johannsson G et al. Long term treatment with growth hormone decreases plasminogen activator and tissue plasminogen activator in growth hormone deficient adults. Thromb Haemost 1996; 76 (3): 422-8.
6. Boonen S, Lesaffre E, Aerssens J. Deficiency of the growth hormone insulin like growth factor 1 axis potentially involved in age related abnormalities in body composition. Gerontology 1996; 42 (6): 330-8.
7. Bengt-Ake Bengtsson. Effects of Growth Hormone Deficiency 4th Annual meeting of the American Academy of anti-aging Medicine, Las Vegas December 1996.
8. Klatz R, MD Grow Young with hGH Harper Collins New York, NY 1997.
The statements found within this web site have not been evaluated by the Food and Drug Administration (FDA) and are intended for informational purposes only. The LindaWade.NET products or recommendations are not intended to diagnose, treat, cure, prevent any disease, or be a substitute for medical care. If any special health conditions exist to please consult a qualified health care professional before using any products.
| |||
|